---
title: "Four-year data shows long-term benefit and safety of AYVAKIT in Indolent Systemic Mastocytosis. 12 presentations at AAAAI Meeting."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277313719.md"
description: "A recent real-world study on AYVAKIT has shown significant improvements in symptoms related to Indolent Systemic Mastocytosis (ISM). 12 data presentations were showcased at the 2026 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), underscoring Blueprint Medicines' leading role in enhancing care for Systemic Mastocytosis (SM). The study was conducted by Blueprint Medicines, now a subsidiary of Sanofi, and was revealed in Cambridge, Massachusetts on February 28, 2026."
datetime: "2026-02-28T14:47:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277313719.md)
  - [en](https://longbridge.com/en/news/277313719.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277313719.md)
---

# Four-year data shows long-term benefit and safety of AYVAKIT in Indolent Systemic Mastocytosis. 12 presentations at AAAAI Meeting.

A recent real-world study on AYVAKIT has shown significant improvements in symptoms related to Indolent Systemic Mastocytosis (ISM). 12 data presentations were showcased at the 2026 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), underscoring Blueprint Medicines' leading role in enhancing care for Systemic Mastocytosis (SM). The study was conducted by Blueprint Medicines, now a subsidiary of Sanofi, and was revealed in Cambridge, Massachusetts on February 28, 2026.

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BPMC.US](https://longbridge.com/en/quote/BPMC.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Sanofi: Information concerning the total number of voting rights and shares - April 2026](https://longbridge.com/en/news/286946199.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts | ONC Stock News](https://longbridge.com/en/news/287198763.md)
- [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md)